Rapid Micro Biosystems
Rapid Micro Biosystems provides innovative products for faster detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products.
Rapid Micro Biosystems provides innovative products for faster detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. The Growth Direct™ System is purpose built for microbial quality control in pharmaceutical manufacturing, detecting contamination earlier and automating the analysis and enumeration of growing colonies. The Growth Direct™ System is easy to validate and does not destroy samples. The device delivers compelling economic benefits to manufacturers, while improving their quality process. The system allows the microbiologist to focus on higher value work, only interacting with samples when a contamination is found. Equivalence studies have shown that the system typically detects a contaminant in about half the time of compendial methods. The Growth Direct™ System is not an alternative method, simplifying validation requirements. The device is non-destructive and uses no reagents, allowing for microbial identification when needed.
Contact Details:
Phone: 781-271-1444
Web: www.rapidmicrobio.com
Email: info@rapidmicrobio.com
Address: One Oak Park Drive, Bedford, MA 01730
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
